Rucaparib: A Review in Ovarian Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

18 citing papers in PubMed.

1. Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.Journal of clinical medicine · 2026
   Review
2. Synthesis of Functionalized Benzocycloheptene Analogs.Essential chem · 2025
   Article
3. Ovarian cancer: Diagnosis and treatment strategies (Review).Oncology letters · 2024
   Review
4. Advancing cancer therapy: new frontiers in targeting DNA damage response.Frontiers in pharmacology · 2024
   Review
5. DNA repair pathways in breast cancer: from mechanisms to clinical applications.Breast cancer research and treatment · 2023
   Review
6. Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.Acta pharmaceutica Sinica. B · 2023
   Review
7. PARP-1: a critical regulator in radioprotection and radiotherapy-mechanisms, challenges, and therapeutic opportunities.Frontiers in pharmacology · 2023
   Review
8. First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer.Cureus · 2022
   Article
9. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.Cell death & disease · 2022
   Article
10. Detection ofCancers · 2022
    Article
11. Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.Journal of medicinal chemistry · 2022
    Review
12. Biochemical, Structural Analysis, and Docking Studies of Spiropyrazoline Derivatives.International journal of molecular sciences · 2022
    Article
13. Recent advancements of antiangiogenic combination therapies in ovarian cancer.Cancer treatment reviews · 2021
    Review
14. Global changes to the chemotherapy service during the covid-19 pandemic.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2021
    Article
15. Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.World journal of gastrointestinal oncology · 2021
    Review
16. The PARP Way to Epigenetic Changes.Genes · 2021
    Review
17. Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.Journal of clinical medicine · 2020
    Article
18. Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists.Cancers · 2019
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as